Table 1 Characteristics of included primary studies
Design (n = 62) | N (%) |
Survey | 23 (37.1) |
Randomized controlled trial | 13 (21.0) |
Observational study | 9 (14.5) |
Pilot study | 5 (8.1) |
Qualitative study | 3 (4.8) |
Phenomenology | 2 (3.2) |
Case report | 2 (3.2) |
Protocol for a randomized controlled trial | 2 (3.2) |
Pre experimental study | 1 (1.6) |
Quality improvement study | 1 (1.6) |
Descriptive study | 1 (1.6) |
Countries (n = 62) | N (%) |
United States | 27 (43.5) |
Canada | 9 (14.5) |
Australia | 9 (14.5) |
Israel | 8 (12.9) |
United Kingdom | 3 (4.8) |
Denmark | 1 (1.6) |
France | 1 (1.6) |
Germany | 1 (1.6) |
Italy | 1 (1.6) |
Mexico | 1 (1.6) |
Spain | 1 (1.6) |
Type of cancer (n = 18,684) | N (%) |
Gastrointestinal (including colorectal, intestinal, liver, oesophageal, oral, pancreas, rectal, stomach) | 2288 (12.2) |
Breast | 2236 (12.0) |
Genitourinary (including bladder, cervical, ovarian, peritoneal, prostate, renal, testicular, vaginal) | 1835 (9.8) |
Hematologic (including leukemia, lymphoma, multiple myeloma, myelodysplastic syndrome) | 1655 (8.9) |
Lung | 1615 (8.6) |
Skin (including melanoma) | 292 (1.6) |
Neurological (including brain, central nervous system, neuroendocrine) | 291 (1.6) |
Head and neck | 287 (1.5) |
Sarcoma | 160 (0.9) |
Hepatobiliary | 36 (0.2) |
Kidney | 16 (0.1) |
Musculoskeletal | 13 (0.1) |
Thyroid | 11 (0.1) |
Not reported | 7,949 (42.5) |
Sex of participants (n = 20,069) *include protocols | N (%) |
Female | 9857 (49.1) |
Male | 9627 (48.0) |
Not reported | 585 (2.9) |